2020
DOI: 10.1111/dth.14147
View full text
|
Sign up to set email alerts
|
Share

Abstract: Intravenous immunoglobulin (IVIg) is increasingly used for the treatment of inflammatory and autoimmune diseases. Although skin reactions to IVIg therapy are usually minor, rare, and not life-threatening, dermatologists need to recognize the nature of these adverse reactions. We describe a 33-year-old man suffering from demyelinating polyneuropathy who developed dyshidrotic eczema on the palms and flaky grayishwhite scales on an erythematous base on his face after the administration of IVIg.